Cordio
Download as PPTX, PDF0 likes300 views
Cordio, founded in 2013, has developed a non-invasive mobile monitoring solution that alerts CHF patients to deterioration through voice analysis, allowing for timely medical intervention. The technology aims to reduce hospitalizations and healthcare costs by enabling proactive monitoring of CHF patients. With promising results from clinical studies, Cordio anticipates a straightforward regulatory pathway for market entry within 12 months.
Cordio
- 1. Early Detection of CHF Deterioration Early Detection of CHF Deterioration Early Detection of CHF Deterioration zeev@cordio-med.com www.cordio-med.com 1 Ze’ev Schlik, co-founder and CTO
- 2. Cordio Background • 2013: • Established by experienced multi-discipliner team with ambitious vision • Founders took upon themselves and concluded: • Initial development of a prototype solution • Preliminary single centre clinical study • Initial IP protection • Q1 2015: • First round of investment was concluded with Israel Chief Scientist and VC/Angel investors to accelerate further R&D • Q2 2016: • 1st generation fully operational solution is in place • A multi-centre clinical study is underway, with positive results to date • National and international patent applications filed Voice Analysis Acoustical Analysis CHF World (Medical) Mobile World Based on the current assessment that the solution will have a straightforward regulatory pathway, Cordio anticipates time to market to be about 12 months.
- 3. CHF Deterioration Process CHF is a chronic, progressive condition in which the heart pumps inefficiently. If left untreated fluids accumulate in air sacs If not well-controlled fluid accumulates around lungs Cordio solution provides early alert on CHF deterioration and allows simple treatment before the appearance of symptoms CHF Symptoms are fatigue, shortness of breath, swelling, and they appear after fluids were accumulated in air sacs. At this stage aggressive treatment and hospitalisation are almost unavoidable. • CHF affects ~10% of 65+ population and In England ~0.85% of the population are CHF diagnosed patients (~500,000) • 50% of CHF patients die within 5 years of diagnosis • Once diagnosed, CHF patient will be hospitalised ~2 times a year (in average) • Reduction of 30% in hospitalisation is an immediate achievable task
- 4. • Device-free, non-invasive, mobile monitoring solution for CHF patients • Alerts on-time to CHF deterioration through free speech into a smartphone app • Dramatically reduces healthcare costs and saves lives Cordio Technology, How Does it Work ? An automated real-time voice-analysis workflow detects early build-up of fluids in the patient’s lungs before the appearance of physical symptoms Patient’s voice is captured by the Smartphone App and sent for analysis (cloud) Alerts are generated once pre-defined threshold is crossed1 2 3 • A personal baseline of voice features is created as the patient uses the Cordio app. • Unacceptable deviations this baseline trigger early alerts to CHF deterioration. • These alerts permit home- or clinic-based medical intervention that could prevent hospitalisation Highly Sensitive Acoustical Analysis of Lung Fluid Anatomy
- 5. Typical CHF Deteriorating Patient 10 days Possible Intervention HospitalisationRoutine Monitoring Aggressive treatment takes effect 7 days Alert Alert Alert 4 days Death on 22nd Hospitalisation From ongoing clinical trial
- 6. Stable CHF Patients With Gradual Deterioration (at home) Gradual change over 4 months
- 7. Health Care • Proactive remote routine treatment and follow-up • Fewer hospitalizations • Fewer physician office visits • Simple and cost effective operation model Patients • Simple on-time self monitoring • Supports maintaining stable condition and preventing deterioration • Better quality of care • Less hospitalizations Value Proposition
- 8. Early Detection of CHF Deterioration Early Detection of CHF Deterioration THANK YOU zeev@cordio-med.com www.cordio-med.com 8 Ze’ev Schlik, co-founder and CTO